InMode Ltd announces a new FDA clearance to market the Morpheus8 Body handpiece and Morpheus8 Platform.
Morpheus8 Body is an intelligent, programmable, full body fractional technology designed to deliver clinically proven RF energy up to a thermal depth of 8mm (7mm pin depth + an additional 1mm thermal profile), with its 40 gold coated pins.
FDA cleared to penetrate subdermal tissue with a thermal profile of 8mm, the Morpheus8 Body handpiece is designed to provide physicians with a faster, bigger, and better solution to deliver customizable full body fractional treatments, according to a news release from the company.
The new Morpheus8 Body will be launched on a new Morpheus8 Platform, a state-of-the-art workstation complete with dual handpieces and four fractional tips with different microneedle configurations (Prime 12 pin, Resurfacing 24 pin, Morpheus8 24 pin, and Body 40 pin). The Morpheus8 Platform provides physicians with a stand-alone solution for fractional RF, ranging from the Morpheus8 Prime for the treatment of delicate areas with high tissue curvature, to the Morpheus8 Body for large zones.
“With InMode being the leader in the RF fractional space, the addition of these new treatment modalities can provide a customizable, full body solution for each patient. True innovation in the industry has become scarce and this is where InMode will continue to thrive. We are excited about the new treatment capabilities for both our physicians and their patients.”
Shakil Lakhani, InMode President of North America
[Source(s): InMode Ltd, PR Newswire]
